Lnc-PKNOX1-1 inhibits tumor progression in cutaneous malignant melanoma by regulating NF-κB/IL-8 axis

Anlan Hong1, Meng Cao1, Dongqing Li1

  • 1Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.

Carcinogenesis
|October 16, 2023
PubMed

Insights

A novel long non-coding RNA, lnc-PKNOX1-1, acts as a tumor suppressor in melanoma. Its reduced expression correlates with advanced disease, and it inhibits melanoma cell growth and spread by regulating interleukin-8 (IL-8).

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cutaneous malignant melanoma is a deadly skin cancer.
  • Long non-coding RNAs (lncRNAs) play roles in melanoma's biological behavior.
  • Identifying novel regulatory mechanisms is crucial for melanoma treatment.

Purpose of the Study:

  • To investigate the function and molecular mechanisms of a novel lncRNA, lnc-PKNOX1-1, in melanoma.
  • To assess lnc-PKNOX1-1 as a potential diagnostic biomarker and therapeutic target.

Main Methods:

  • Reverse transcription-quantitative PCR to assess lnc-PKNOX1-1 expression.
  • In vitro and in vivo experiments to evaluate melanoma cell proliferation, migration, and invasion.
  • Protein microarray, Western blot, and ELISA to elucidate molecular mechanisms involving interleukin-8 (IL-8) and p65 phosphorylation.

Main Results:

  • lnc-PKNOX1-1 expression was significantly decreased in melanoma cells and tissues.
  • Low lnc-PKNOX1-1 expression correlated with invasive type and increased Breslow thickness.
  • lnc-PKNOX1-1 inhibited melanoma cell proliferation, migration, and invasion, partly via negative regulation of IL-8.

Conclusions:

  • lnc-PKNOX1-1 functions as a tumor suppressor in melanoma.
  • lnc-PKNOX1-1 may serve as a novel diagnostic biomarker for melanoma.
  • Targeting lnc-PKNOX1-1 presents a potential therapeutic strategy for melanoma.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K